Score improves prediction of chemotherapy-related cardiotoxicity

Addition of a “simple” clinical risk score on top of current risk assessment tools may improve identification of patients undergoing chemotherapy likely to develop treatment-related cardiotoxicity, researchers reported.
The use of the novel RE-ACT score on top of the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) score improved the discrimination of either tool when used alone, according to data published in JACC: CardioOncology.
“Several risk factors for anthracycline-induced cardiotoxicity have been identified, including advanced age, preexisting

Foundayo noninferior to insulin glargine for CV outcomes

The oral GLP-1 orforglipron was noninferior to insulin glargine for major adverse cardiovascular events in patients with type 2 diabetes at high CV risk, according to results of the ACHIEVE-4 trial.
For ACHIEVE-4, presented at the European Association for the Study of Diabetes Annual Meeting and simultaneously published in The Lancet, researchers randomly assigned 2,749 patients (mean age, 63 years; 38% women) with type 2 diabetes (mean HbA1c, 8.2%), overweight or obesity (BMI 25 kg/m2; mean, 33 kg/m2) and established cardiovascular disease or chronic kidney disease to orforglipron (Foundayo,